Geode Capital Management
QTTB icon

Geode Capital Management’s Q32 Bio QTTB Stock Holding History

Geode Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
122,690
+4,538
+4% +$37.9K ﹤0.01% 3244
2026
Q1 		$759K Buy
118,152
+12,039
+11% +$57.2K ﹤0.01% 3442
2025
Q4 		$352K Buy
106,113
+17,617
+20% +$49.8K ﹤0.01% 3721
2025
Q3 		$175K Buy
88,496
+26,897
+44% +$51.7K ﹤0.01% 3966
2025
Q2 		$91.8K Sell
61,599
-75,910
-55% -$129K ﹤0.01% 4082
2025
Q1 		$227K Buy
137,509
+4,246
+3% +$11.4K ﹤0.01% 3799
2024
Q4 		$459K Buy
133,263
+1,495
+1% +$47.2K ﹤0.01% 3625
2024
Q3 		$5.88M Buy
131,768
+24,114
+22% +$886K ﹤0.01% 2676
2024
Q2 		$1.93M Buy
107,654
+89,688
+499% +$2.15M ﹤0.01% 3135
2024
Q1 		$306K Sell
17,966
-4
-0% -$55 ﹤0.01% 3790
2023
Q4 		$197K Hold
17,970
– – ﹤0.01% 3949
2023
Q3 		$379K Sell
17,970
-2,319
-11% -$47.3K ﹤0.01% 3709
2023
Q2 		$323K Sell
20,289
-1,156
-5% -$20.8K ﹤0.01% 3824
2023
Q1 		$398K Hold
21,445
– – ﹤0.01% 3735
2022
Q4 		$486K Sell
21,445
-47
-0.2% -$1.25K ﹤0.01% 3669
2022
Q3 		$622K Buy
21,492
+52
+0.2% +$2.12K ﹤0.01% 3614
2022
Q2 		$760K Sell
21,440
-23,926
-53% -$817K ﹤0.01% 3540
2022
Q1 		$2.48M Buy
45,366
+733
+2% +$45.5K ﹤0.01% 3150
2021
Q4 		$2.92M Buy
44,633
+4,744
+12% +$460K ﹤0.01% 3181
2021
Q3 		$5.65M Buy
39,889
+812
+2% +$103K ﹤0.01% 2837
2021
Q2 		$5.11M Buy
39,077
+8,237
+27% +$1.03M ﹤0.01% 2892
2021
Q1 		$5.22M Buy
30,840
+3,590
+13% +$756K ﹤0.01% 2770
2020
Q4 		$5.54M Buy
27,250
+2,209
+9% +$427K ﹤0.01% 2548
2020
Q3 		$4.82M Buy
25,041
+117
+0.5% +$26.2K ﹤0.01% 2419
2020
Q2 		$6.81M Buy
24,924
+4,000
+19% +$1.07M ﹤0.01% 2160
2020
Q1 		$5.85M Buy
20,924
+1,120
+6% +$343K ﹤0.01% 2050
2019
Q4 		$7.38M Buy
19,804
+941
+5% +$270K ﹤0.01% 2218
2019
Q3 		$6.14M Buy
18,863
+1,176
+7% +$400K ﹤0.01% 2258
2019
Q2 		$6.23M Buy
17,687
+8,333
+89% +$3.27M ﹤0.01% 2256
2019
Q1 		$4.67M Buy
9,354
+852
+10% +$381K ﹤0.01% 2375
2018
Q4 		$3.42M Buy
8,502
+2,332
+38% +$882K ﹤0.01% 2456
2018
Q3 		$2.54M Buy
6,170
+838
+16% +$285K ﹤0.01% 2757
2018
Q2 		$1.96M Buy
+5,332
New +$1.91M ﹤0.01% 2872

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's QTTB Position: Q2 2026 in Review

Geode Capital Management increased its Q32 Bio (QTTB) stake by 3.8% in Q2 2026, buying an estimated $37.9K and bringing the position to 122,690 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #3244.

Geode Capital Management first reported a position in QTTB in Q2 2018 and has held it in 33 quarters since. The position peaked at $7.38M in Q4 2019. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Geode Capital Management held 122,690 shares of Q32 Bio worth $1.56M as of Q2 2026.
  • Geode Capital Management bought 4,538 Q32 Bio shares in Q2 2026, an estimated $37.9K.
  • Q32 Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3244 holding.
  • Geode Capital Management first reported a position in Q32 Bio in Q2 2018 and has held it in 33 quarters since.
  • Geode Capital Management's Q32 Bio position peaked at $7.38M in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.